Saturday, May 16, 2026, San Antonio, Texas, 6:00 AM – 7:30 AM Central Time (7:00 AM – 8:30 AM Eastern Time)

Recent Advances in Cancer Care — New Paradigms, Novel Agents and What It Means for the Oncology Nurse: Optimizing the Use of CDK4/6 Inhibitors in the Management of HR-Positive Breast Cancer

A Complimentary NCPD Symposium Held During the 51st Annual ONS Congress

 

 

 

Register for in-person Register for webcast

Program Schedule — Central Time
5:30 AM – 6:00 AM — Registration and Breakfast
6:00 AM – 7:30 AM — Educational Meeting

Location
San Antonio Marriott Rivercenter
101 Bowie St
San Antonio, Texas
Hotel Phone: (210) 223-1000

Meeting Room
Grand Ballroom A-F (Third Floor)
 
 
Faculty
Marissa Marti-Smith, DNP, APRN, AGNP-C, AOCNP
Nurse Practitioner
Texas Oncology-Baylor Charles A Sammons Cancer Center
Dallas, Texas

Ruth O’Regan, MD
Chair, Department of Medicine
Charles A Dewey Professor of Medicine
University of Rochester
Rochester, New York

Additional faculty to be announced.
Moderator
Rita Nanda, MD
Director, Breast Oncology
Associate Professor of Medicine
Section of Hematology/Oncology
The University of Chicago
Chicago, Illinois


Meeting space has been assigned to provide a symposium supported by Lilly and Novartis during the Oncology Nursing Society’s (ONS) 51st Annual Congress, May 13-17, 2026 in San Antonio, TX. The Oncology Nursing Society’s assignment of meeting space does not imply product endorsement.
Program Schedule — Central Time
5:30 AM – 6:00 AM — Registration and Breakfast
6:00 AM – 7:30 AM — Educational Meeting

Topics to Be Discussed

  • Appropriate Risk Assessment for Patients with HR-Positive, HER2-Negative Localized Breast Cancer; Rationale for the Use of CDK4/6 Inhibitors for Those at High Risk for Recurrence
  • Role of Adjuvant CDK4/6 Inhibitor Therapy for High-Risk HR-Positive, HER2-Negative Localized Breast Cancer
  • CDK4/6 Inhibitors for HR-Positive Metastatic Breast Cancer
  • Cytopenias Associated with CDK4/6 Inhibitors
  • Gastrointestinal Adverse Events Documented with CDK4/6 Inhibitors
  • Rarer but Potentially Serious Toxicities Associated with One or More CDK4/6 Inhibitors
  • Practical Considerations with the Administration of CDK4/6 Inhibitors

Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of breast cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Discern the mechanism by which the cyclin-dependent kinase (CDK) pathway contributes to breast cancer proliferation and growth, and consider the implications for the management of hormone receptor (HR)-positive disease.
  • Understand how various clinical and biological factors, such as age or menopausal status, tumor size or grade and nodal involvement, affect the risk of disease recurrence, and use this information to personalize the selection of adjuvant systemic therapy for patients with newly diagnosed HR-positive, HER2-negative localized breast cancer.
  • Consider available clinical trial findings with CDK4/6 inhibitors for localized HR-positive, HER2-negative breast cancer, and identify patients for whom adjuvant treatment with one of these agents would be appropriate.
  • Appraise published findings from randomized clinical trials establishing the efficacy and safety of CDK4/6 inhibitors in patients with HR-positive metastatic breast cancer in order to understand the risks, benefits and optimal clinical use of these agents in various patient subgroups.
  • Recognize adverse events and other common side effects associated with different CDK4/6 inhibitors for breast cancer, and tailor therapy for patients with preexisting medical conditions and relevant comorbidities.
  • Develop preventive and emergent strategies to reduce or ameliorate the various toxicities associated with CDK4/6 inhibitors.

Accreditation Statement
Research To Practice is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements
This educational activity for 1.5 contact hours is provided by Research To Practice.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
This program will be submitted for ONCC/ILNA certification.

Credit Form
To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. A credit form link will be given to each participant as part of the meeting course materials.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by Research To Practice or the American Nurses Credentialing Center.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Ms Marti-Smith — Consulting Agreements: Amplity; Speakers Bureaus: AstraZeneca Pharmaceuticals LP, Biotheranostics Inc, A Hologic Company, Daiichi Sankyo Inc, Stemline Therapeutics Inc; Nonrelevant Financial Relationships: ASCO Quality Care Symposium, Clinical Care Options, Kaplan, OncLive, Oncology Nursing News. Additional faculty to be announced.

MODERATOR — Dr Nanda — Advisory Committees: AstraZeneca Pharmaceuticals LP, Corcept Therapeutics Inc, Daiichi Sankyo Inc, Exact Sciences Corporation, Gilead Sciences Inc, Lilly, Mabwell Therapeutics Inc, Merck, Pfizer Inc, Summit Therapeutics; Contracted Research: Arvinas, AstraZeneca Pharmaceuticals LP, Corcept Therapeutics Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Jazz Pharmaceuticals Inc, Mabwell Therapeutics Inc, Merck, Pfizer Inc, Relay Therapeutics.

RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from Lilly and Novartis.

San Antonio Marriott Rivercenter
101 Bowie St
San Antonio, TX 78205
Hotel Phone: (210) 223-1000

Meeting Room
Grand Ballroom A-F (Third Floor)

Directions
The Marriott Rivercenter hotel is conveniently located within walking distance (1.5 blocks) of the Henry B González Convention Center, where the 2026 ONS Congress is taking place.

 
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of breast cancer.

No registration fee is charged for this event. For the in-person symposium in San Antonio, preregistration is required as seating is limited.

NOTICE
Registration for this event is independent of registration for the 2026 ONS Congress.

IN-PERSON registration for nurses and healthcare providers

I am a practicing nurse or healthcare provider involved in the care of patients with cancer.

IN-PERSON Registration
for clinicians »
IN-PERSON registration for other/industry professionals*

Please note, a limited number of seats are available to other/industry professionals on a first come, first served basis.

IN-PERSON Registration
for nonclinicians »
 
* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
WEBCAST registration for all professionals

We will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.

REGISTRATION FOR WEBCAST »
Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you require any physical, dietary or other accommodations, please call us at (800) 233-6153 before the event.

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.